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Abstract:  
In this research, we have demonstrated that miRNA146b-5p (miR146b) is a hormonally 
regulated miRNA that participates in the maintenance of mamry alveolar progenitors during 
pregnancy and lactation by preferential regulation of STAT3β.  Recently, our laboratory isolated 
distinct ductal, alveolar and multipotent mammary progenitors by single-cell cloning of the 
COMMA-D (CD) cell line.  Molecular characterization of the distinct clones showed 
significantly higher expression of miR146b in the CD derived alveolar compared to the ductal 
and multipotent progenitors.  Additionally, there was a significant rise in miR146b mRNA levels 
in the pregnant and lactating mouse mammary glands and in virgi glands following in vivo 
administration of estrogen and progesterone.  An analysis of mammary epithelial subpopulations 
during pregnancy showed a significantly higher expression of miR146b in the alveolar luminal 
progenitors compared to stem and differentiated luminal cells.  Induced knockdown of miR146b 
led to increased cell death in the CD derived alveolar progenitors and a significant reduction in 
the percentage of primary mouse mammary alveolar luminal progenit rs.  Among several of the 
candidate targets, miR146b regulated STAT3β and to a lesser extent STAT3α.  A reporter 
construct using STAT3α 3’UTR inserted downstream of the firefly luciferase showed a 
significant reduction in reporter activity when cells overexpressed miR146b.  As an imbalance in 
miR146b has been linked to human breast cancers, regulation of STAT3 isoform  may be a 
novel mechanism by which miR146b participates in breast carcinogenesis. 
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Prospective isolation and characterization of committed and multipotent progenitors from 
immortalized mouse mammary epithelial cells with morphogenic potential: 
 
Our knowledge of the components of the mammary epithelial cell hierarchy has expanded in 
recent years as a result of the development of strategies to prospectively isolate phenotypically 
distinct subsets of mammary cells using fluorescence-activated cell sorting (FACS) and 
assessing the properties of these cells using in vitro and in vivo functional assays. 
Mammary stem cells (MaSCs) are presumed to be important for both mammary development 
and maintaining tissue homeostasis. The cells give rise to mature epithelium of either the luminal 
or myoepithelial lineage via a series of lineage-restricted intermediates. The luminal lineage can 
be further subdivided into ductal cells that line the ducts, and alveol r luminal cells that 
constitute the alveolar units which arise during pregnancy. In contrast, myoepithelial cells are 
specialized, contractile cells located at the basal surface of the epithelium adjacent to the 
basement membrane [1]. In general, the stem cells are thought to give rise to committed 
progenitor cells for either the myoepithelial or luminal epithelial lineages (ductal and alveolar 
sublineages), but the precise number and nature of the intermediates remain elusive [1]. A 
hypothetical model has been proposed by Kittrell et al. [2] where the mammary epithelial cell 
hierarchy begins with asymmetric self-renewal in the stem c lls, which generate multipotent and 
bipotent ductal and alveolar progenitor cells.  Ductal and alveolar progenitor cells give rise to 
luminal and myoepithelial-restricted progenitors (Fig.1), which then form the differentiated 
luminal and differentiated myoepithelial cells respectively. The observation of epithelial 
outgrowths with either ductal-only or alveolar-only characteristics that contain both luminal and 
myoepithelial elements following mammary cell transplantation lends support to this model.   
Previous studies define the subpopulations enriched in stem cells by theexpression of unique 
surface markers, lineage-negative (lin-) CD24+CD29high and lin-CD24+CD49fhigh, luminal 
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progenitors by lin-CD29lowCD24+CD61+, differentiated estrogen receptor-positive (ER+) luminal 
cells by CD24+CD133+ and myoepithelial progenitors by CD29lowCD24low [3,4,5]. Regan et al. 
[6] showed that the c-Kit signaling pathway is required for the normal function of mammary 
epithelial progenitors.  In this study, CD24+/Low Sca-1- CD49fLow was demonstrated to represent a 
marker for for the myoepithelial cells, CD24+/Low Sca-1- CD49fHigh for the mammary stem cells, 
CD24+/High Sca-1- for the luminal ER- progenitor cells, and CD24+/High Sca-1+ for luminal 
differentiated ER+ cells.  Additionally, this study, demonstrated that the majority of luminal ER- 
progenitors are c-Kit+, but also most stem cells and the differentiated cell populations are c-Kit+ 
[6].These studies facilitated the analysis of the mammary epithelial subpopulations, which is a 
key for understanding mammary epithelial stem/progenitor cells in normal tissue biology and 
carcinogenesis. 
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Figure.1: Hypothetical model of stem cell differentiation during mammary gland 
development. Mammary gland development begins by asymmetric self-renewal in a stem cell, 
which generates multipotent and bipotent ductal and alveolar progenitor cells [2].   
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Using single-cell cloning, Dr. Behbod’s laboratory isolated distinct mammary progenitor 
populations from the CD cell line, which was originally derived from mid-pregnancy BALB/c 
mouse mammary glands. This cell line is unique in that transplantation of cells into the
epithelium-free fat pads of syngenic female mice generates mammary ductal and alveolar 
structures.  
In this study, CDβ cells were stained using Hoechst dye 33342, followed by FACS analysis nd 
sorting of each population. Cells that effluxed the dye appeared on the left side of a FACS 
analysis panel were referred to as side population “SP” cells.  This elevated rate of Hoechst 
efflux was previously suggested as being due to expression of the Adenosine Binding Cassette 
(ABC) trans-membrane pump (Abcg2) which pump vital dyes out of cells [7].  Cells that 
retained the dye appeared on the right side and were referred to as non-side population “NSP” 
cells. To assess the stem progenitor cell potential of the SP cells compared to the NSP cells,  
single cells were sorted from each region, expanded in vitro and transplanted to assess their 
outgrowth potential.  As shown, in (Fig. 2), Transplantation of the SP3 clone generated only 
alveolar structures in vivo and is referred to herein as an “alveolar progenitor clone”.  
Transplantation of NSP2 generated only ductal structures and is referred to herein as a “ductal 
progenitor clone”.  Transplantation of clones NSP1 and NSP5 generated ducts and alveolar 
structures and are referred to herein as “multipotent progenitor clones”.  Stimulation of mice 
transplanted with cells from the “alveolar progenitor” and the “ductal progenitor” clones with 
pituitary isografts results in formation of milk droplets in the alveolar progenitor clone, in 
contrast to the ductal progenitors, which don’t make milk but produces intraductal hyperplasia. 
Pituitary isografts release pregnancy hormones including E+P and prolactin.  Furthermore, the 
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clones’ outgrowths showed an appropriate basal-luminal orientation with a basal expression of 
SMA, CK5 and p63, and luminal expression of CK8 and NKCC1.  
These distinct progenitor clones have been utilized as an experimental tool in this thesis, to 
further investigate the molecular mechanisms involved in mammary lineage maintenance and 
commitment. 
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Figure. 2 Whole-mount and hematoxylin and eosin staining of outgrowths generated from 
the CDβ parental line and CDβ progenitor clones. (A and E) Transplantation of COMMA-D 
cell line engineered to express β-galactosidase (CDβ) parental cell line generates outgrowths 
containing ductal and alveolar structures. (B and F) Ductal progenitor cells give rise to 
outgrowths containing ducts only. (C and G) Alveolar progenitor clone generates mainly alveoli 
and a limited number of small ducts. (D and H) Multipotent progenitor clone generates 
outgrowths containing ductal and alveolar structures.  Figures 2A to D are whole-mount-stained 
images taken at 3.2x original magnification.  Figures 2E to 1H are hematoxylin and eosin-stained 
images taken at 10x original magnification [2]. 
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Mammary gland development 
 The development of mammary gland is a highly dynamic process and involves the distinct 
stages of embryonic, pubertal, pregnancy, lactation and involution.  Hormones and growth 
factors play a role in these different stages of mammary development and also implicated in 
breast cancer [8].  During pregnancy, the hormone progesterone (P) in combination with 
prolactin (PRL) induce alveolar proliferation (lactogenesis I), the functional differentiation and 
milk secretion are achieved shortly before parturition (lactogenesis II) [8].  Lactation requires the 
production of specific cells that can synthesize and secrete copious amounts of milk.  At the end 
of the lactation period, the mammary alveolar compartment regresses rapidly, and the 
morphology of the gland resembles that of a mature virgin.  It is generally agreed that during 
involution, the differentiated alveolar cells undergo apoptosis, and that the lveolar compartment 
is reconstituted in subsequent pregnancies from undifferentiated mammary stem cells or alveolar 
precursors [9].  
Hormonal regulation of alveolar differentiation: In the late fifties, a series of experiments 
defined the minimal hormonal requirements for mammary gland development in mice [10], and 
rats [11]. Hormone replacement in animals that have been hypophysectomized, ovariectomized, 
and adrenalectomized established that additive and sequential treatment with 17-b-estradiol, 
progesterone, and prolactin in conjunction with cortisol and GH can recapitulate mammary gland 
development. Furthermore, findings indicate that estrogen can targethe s romal and epithelial 
compartments of the mammary gland, progesterone can target the epi lium, and prolactin can 
target the epithelium and potentially the stroma [12]. Since most cell  that proliferate in response 
to estrogen treatment in vivo do not contain estrogen receptors, it is possible that estrogen mi ht 
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probably have indirect mechanisms, which include the induction of local growth factors or their 
receptors [12].  
Genetic Pathways Controlling Mammary Development: Among the growth factors that have 
demonstrated roles, or are highly implicated, in mammary growth and differentiation are the 
EGF, TGF-β, FGF, and IGF families [13]. Ductal elongation and branching during puberty is 
controlled by inhibinβ, CSF-1, the progesterone and estrogen receptor, and wnt. Proliferation and 
differentiation of mammary alveolar cells is controlled by the prolactin receptor, STAT5, 
RANKL, cyclinD1, p27, Id2, and C/EBPβ. Mammary function during lactation is controlled by 
prolactin through STAT5, and tissue remodeling and cell death during involution by STAT3, 
bax, and bcl-x [14]. Among these factors, we focused on STAT3 and STAT5a due to their 
established role in alveolar development and remodeling. 
  
Signal transducer and activator of transcription 3 (STAT3) in mammary gland 
development and cancer 
 
Signal transducer and activator of transcription 3 (STAT3) is a member of the STAT family of 
transcription factors implicated in growth factor and cytokine signaling.  STAT3 exists in two 
main isoforms: full-length STAT3α and truncated STAT3β; the proteins are generated by 
alternative mRNA splicing of exon 23 [15,16].  In STAT3β, the 55-amino acid C-terminal acidic 
transactivation domain of STAT3α is replaced by seven unique amino acid residues (CT7 
domain) (Fig. 3) [16]. STAT3β has been known to function as a dominant-negative factor by 
inhibiting STAT3α gene transactivation [17,18]. However, more recent studies have 
demonstrated that STAT3β to serve as more than just a dominant-negative regulator, since it 
activates a specific set of genes and possesses non-redundant functions to 
10 
 
STAT3α.  Furthermore, STAT3β over-expression induces apoptosis in some breast cancer cell 
lines [17]. 
During mammary gland development, it has become clear that STAT3 regulates a complex series 
of processes involving alveolar epithelial cell death during involution by maintaining the balance 
of inflammatory and anti-inflammatory signaling [19], and mice with a mammary-specific 
conditional deletion of STAT3 exhibit a notable delay in this process [20].  The contribution of 
specific STAT3 isoforms to mammary involution process is still not known.  However, in this 
study we clearly demonstrate that both isoforms of STAT3 are up- gulated during involution.  It 
would be interesting to decipher the contribution of specific STAT3 isoforms to the mammary 
involution process.   
In breast cancer, STAT3 has been classified as an oncogene because the constitutively active 
STAT3 can mediate oncogenic transformation in cultured cells and tumor formation in nude 
mice [21].  Moreover, a number of independent studies have reported that the majority of 
primary breast cancers exhibit a constitutive activation of STAT3 and that this particular signal 
transducer plays an important role in breast cancer cell growth and metastatic progression 
[21,22,23,24].  Therefore, functional inhibition of STAT3 as part of a targeted therapy for 
advanced breast cancers may prevent the metastatic dissemination of malignant cells [25]. 
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Figure. 3 Differences in STAT3α and STAT3β structure. A: Alternative 3’ splice site use in 
exon 23 generates STAT3α or STAT3β, where the TAD (green) is substituted by a unique 7-aa 
tail (red). DBD, DNA binding domain. STAT3β can be efficiently be phosphorylated at the key 
tyrosine 705 (Y705) but lacks serine 727 (S727) [16], whose phosphorylation stimulates 
transcriptional activity.  B: Immunoblotting with a pan-specific STAT3 antibody detects 
STAT3α and STAT3β in mammary epithelial cell lysates. 
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MicroRNAs: 
MicroRNAs (miRNAs) are a specific class of endogenous non-coding RNAs that are typically 
conserved across species. They are single-stranded RNAs of 21-25 nucleotides in length, and 
function in post-transcriptional gene silencing [26].  
The biogenesis of miRNAs (Fig. 4) begins by RNA polymerase II. Primary miRNAs (pri-
miRNA) are produced from miRNA genes which contain their own promoters, whereas mirtrons 
are formed from splicing stem-loop structures present in pre-mRNA transcripts.  Both of these 
classes undergo additional processing to form precursor miRNAs (pre-miRNA), with pri-
miRNAs requiring the RNase III enzyme Drosha, and the mirtron-derived lariat structures 
employing the lariat-debranching enzyme (DBR1).  Exportin 5 (EXPO5) shuttles pre-miRNAs to 
the cytoplasm, at which point they are processed into mature miRNAs by another RNase III 
enzyme, Dicer.  The dsRNA binding protein (TRBP) binds to Dicer and loa s the miRNA into 
the Argonaute 2 (AGO2) endonuclease.  The Dicer-TRBP-AGO2 complex, ref rred to as RNA-
induced silencing complex (RISC), directs complementary binding of miRNAs to target mRNAs 
(generally in the 3′ untranslated region of the mRNA), and facilitates translational repression by 
promoting mRNA degradation or preventing translation initiation [26].  MiRNAs may regulate 
targets cooperatively, and many demonstrate remarkable promiscuity, targeting several or even 
hundreds of mRNAs [27]. 
MiRNAs have been experimentally linked to both normal physiology and pathology, including 
regulation of developmental processes, proliferation, differentiation and apoptosis.  Loss of 
mature miRNAs resulted in a failure of the cells to differentiate [28,29,30,31], providing 
evidence that miRNAs may also be involved in maintaining stem cell populations by keeping 
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them in an undifferentiated state, controlling stem cell self-renewal and regulating the transition 
of undifferentiated stem cells to more differentiated states [26]. 
 
 
 
Figure.4: A, Biogenesis and function of miRNAs. MiRNAs are transcribed as primary 
miRNAs (pri-miRNA) or are derived from stemloop structures“Mirtrons”within pre-mRNAs. 
Drosha processes pri-miRNAs whereas the stem-loop-derived structures depend on the lariat-
debranching enzyme (DBR1) to form precursor miRNAs (premiRNAs). Exportin 5 (XPO5) 
exports pre-miRNAs into the cytoplasm where they are further processed by the Dicer/TRBP 
complex into mature miRNAs. Argonaute 2 (AGO2) joins the Dicer/TRBP complex to generate 
the RNA-induced silencing complex (RISC) which mediates binding to complimentary 
sequences in target mRNAs and translational repression or mRNA degradation. B, Structure of 
miR-146a/b. Predicted stem-loop structures of miR-146a and miR-146b. The mature miR-146a-
5p and miR-146b-5p differ by only two bases in the 3’region [32]. 
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MiR146a/b in development and cancer: 
Mouse miR146b is located on chromosome 19 at position 19qC3 whereas miR146a is located on 
chromosome 11 at position 11qA5 [33].  Structurally, the mature miR146a and miR146b differ 
by only two nucleotides at the 3’ end, a region that is believed to play a minor role in target 
recognition, and in many instances miR146a and miR146b have demonstrated redun ant 
activities [34].  Mice knockout for miR146a exhibit increased sensitivity to LPS [35,36].  Older 
knockout animals were also noted to have a significantly increased ri k of malignant 
hematolymphoid neoplasia [36].  Interestingly, estrogen stimulation has been reported to 
downregulate the expression of miR146a in splenic lymphocytes and as such miR146a may play 
a role in down-modulating LPS mediated immune responses [37].  As of the writing of this 
manuscript, a miR146b knockout mouse has not been reported.   
There are conflicting reports on the role of miR146a/b in cancer progression.  A study by He, H. 
et al. showed that three miRNAs (miR146, miR221, and miR222) were dramatically 
overexpressed in papillary thyroid cancers (PTC) compared to the adjacent unaffected thyroid 
tissue [38].  This group concluded that among tumors with BRAF mutations, overexpression of 
miR146b was associated with aggressive behavior in PTC tumors.  Bockmeyer et al. [39], 
studied the microRNA profiles of healthy basal and luminal epithelial cells as well as basal and 
luminal breast cancers.  Interestingly, miR146b was shown to be a basal-specific microRNA and 
to be expressed at higher levels in basal-like breast cancers compared to luminal A and B 
subtypes [39].  Garcia et al.  [40] studied the regulation of BRCA1 by the miR146 family, and 
found that miR146a and miR146b expression to be higher in basal-like breast cancer cell lines, a 
subtype which commonly exhibits low or absent BRCA1 expression [41,42].  They also showed 
that miR146a and miR146b precursor transfection increased cell proliferation in HeLa and in 
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MDA-MB-468 cells by targeting the 3’UTR of BRCA1 and down-regulating its expression.  
Furthermore, both miR146a and miR146b were upregulated in triple negative versus ER+/PR+, 
and in the Scarff-Bloom-Richardson (SBR) grade III versus grade II breast tumors [40].  Based 
on this work, miR146a/b may play a role in breast cancer progression.   Conversely, miR146b 
has also been shown to inhibit carcinogenesis.  For example, miR146b was shown to inhibit 
glioblastoma cell migration and invasion by targeting matrix metalloproteinase 16 (MMP16), a 
protease selectively expressed in the brain [43].   Welch and colleagues [44]recently coined the 
term “metastamir” to refer to metastasis regulatory miRNAs that have an impact on critical steps 
in the metastatic cascade, such as epithelial-mesenchymal transition (EMT), apoptosis, and 
angiogenesis [44].  This group has classified miR146a/b as a “metastasis- uppressing 
metastamir”[44].  Bhaumik et al. demonstrated that over-expression of miR146a/b in the highly 
metastatic human breast cancer cell line MDA-MB-231 caused suppression of constitutive NF-
κB activity by down-regulating IRAK1 and TRAF6, two key adaptor/scaffold proteins in the IL-
1 and TLR signaling pathway known to positively regulate NF-κB activity [45].  Furthermore, 
miR146a/b-expressing cells displayed only 45% and 38% of the control migration capacity, 
respectively.  Interestingly, although compromised in their motility and invasiveness, 
miR146a/b-overexpressing cells exhibited no proliferation impairment or apoptosis sensitivity 
relative to control cells [45].  Another study by Hurst et al. [44] revealed that breast cancer 
metastasis suppressor 1 (BRMS1), a nuclear protein that causes suppres ion of cancer metastasis, 
could exert its anti-metastatic action by differentially regulating expression of miR146a and 
miR146b.  In addition, both miR146a/b reduced EGFR expression and suppressed metastasis 
[44].  These findings suggest that miR146a/b may play a dual role in cancer and there is much to 
16 
 
be learned about the mechanism by which these closely related miRNAs may participate during 
various stages of carcinogenesis.    
 
 
In this study, we have identified a hormonally regulated miRNA, miR146b, that plays a 
pivotal role in alveolar progenitor cell maintenance.  Altered expression of miR146b has 
been linked to an invasive and metastatic capacity in diverse cancers.  Finding a 
hormonally regulated miRNA that regulates both the processes of alveolar cell 
maintenance and breast cancer may provide a missing link in the molecular pathways 
implicated in hormonal regulation of human breast cancer.  
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MiR146b is highly expressed in the alveolar progenitor cells 
As described in the introduction, distinct mammary alveolar, ductal and multipotent progenitor 
clones were derived from the CD cell line [2].   An RT2 miRNA PCR array was used to screen 
the specific CD derived clones to screen for changes in the expression of 84 unique miRNAs, 
(Fig. 1A).  This screening showed a set of 74 up-regulated miRNAs in the clones with in vivo 
growth potential (including the alveolar progenitor, ductal progenitor and multipotent 
progenitors) when compared to clones that exhibited no in vivo growth potential.  Twenty 
miRNAs showed a 10 to 20-fold increase, and 14 miRNAs showed > 20-fold increase (Fig. 1A).  
Among those upregulated, miR146b showed >72-fold increase, and miR-203 showed >77-fold 
increase.  To identify whether miR146b, miR203 and other up-regulated miRNAs were 
differentially expressed in the specific progenitor cell clones, RT-qPCR was used on RNA 
derived from progenitor clones grown on Matrigel in three dimension (3D).  MiR146b was the 
only miRNA that showed differential expression as it was highly expressed by the alveolar 
progenitor clone with a 10-fold (± 1.8 SEM) increase compared to the ductal and the multipotent 
progenitor clones (Fig. 1B), while others such as miR203 expression showed no difference 
between the distinct progenitor clones (data not shown).  
To confirm our findings, we used primary mammary epithelial cells (PMEC) isolated from 
female balb/c mice during the various stages of mammary development.  Mammary epithelial 
cells were isolated from virgin, pregnant, lactating and 10 days post-weaning (involuting).  RT-
qPCR showed a 3.5 (6.1± 0.57 SEM vs. 2.3± 0.76 SEM) fold increase in miR146b expression in 
the PMEC of pregnant and a 6.3 (10.8± 1. 03 SEM vs. 2.3± 0.76 SEM) fold increase in l ctating 
mice compared to PMEC from virgin and post-weaning mice (Fig. 1C).  Because the pattern of 
expression of miR146a and miR146b is similar and the isoforms are co-r gulated in normal 
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mammary cell lines and in breast cancer cell lines [40], RT-qPCR was used to examine miR146a 
levels as well.  The results showed that miR146a levels increased similarly during pregnancy and 
lactation.  However, the fold changes in miR146a during mammary developm nt were not as 
great as those of miR146b (Fig. 1C).   
Recently, the progenitor and differentiated cells in the mouse mammary glands and human breast 
were phenotypically and functionally characterized by fluorescence-activated cell sorting 
(FACS) followed by transplantation.  These studies define the subpopulati ns enriched in stem 
cells by the expression of unique surface markers, lineage-negative (lin-) CD24+CD29high and 
lin-CD24+CD49fhigh, luminal progenitors by lin-CD29lowCD24+CD61+, differentiated 
estrogen receptor-positive (ER+) luminal cells by CD24+CD133+ and myoepithelial progenitors 
by CD29lowCD24low [3,4,5].  To find the mammary epithelial sub-population with the highest 
miR146b expression, the luminal progenitors (lin-CD29lowCD24+CD61+), stem c lls (lin-
CD29highCD24+), and differentiated luminal cells (lin-CD29lowCD24+CD61-) were sorted 
from the balb/c mouse mammary glands during pregnancy, followed by RNA extraction and RT-
qPCR for miR146b expression.  The results revealed that miR146b expression levels were 3.4-
fold (11.8±0.59 SEM) higher (p<0.05) in the luminal progenitors compared to the stem cells 
(3.4±0.87 SEM) and 1.3-fold higher (p=0.05) compared to the differentiated luminal cells 
(9.0±0.47 SEM) (Fig.1D & E).  These data supported the earlier results that CD derived alveolar 
progenitor cells express significantly higher levels of miR146b.   In summary, miR146b levels 
rise during lactation and pregnancy.  Since expression was significantly higher in the luminal 
alveolar progenitor and differentiated luminal cells compared to stem cells, miR146b may play a 
functional role in these cells.    
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Figure 1.  MiR146b expression is upregulated in the CD derived alveolar progenitor cells 
and in mouse mammary glands during pregnancy and lactation. (A) An RT2 miRNA PCR 
array was used to screen for miRNAs differentially expressed in CD clones with in vivo growth 
potential normalized to CD clones lacking in vivo growth potential.  (B) Quantitative PCR of 
miR146b expression in three CD derived clones grown for 7 days on Matrigel®.   Ductal and 
alveolar progenitor clones were normalized to the multipotent clone (n=4; * indicates P<0.05).  
(C) Quantitative PCR of miR146b and miR146a expression in PMECs from mice which were 
virgin, pregnant, lactating, or 10 days post-weaning (n=3; letters indicate treatment groups which 
differ, P<0.05). (D) Representative histograms of the three mammary subpopulations lin-
CD24+CD29hi (stem cells), lin-CD24+CD29loCD61+ (luminal progenitor cells) and lin-
CD24+CD29loCD61- (differentiated luminal cells) analyzed in the epithelial population from the 
mammary glands of pregnant mice.  The subpopulations were sorted by FACS, and (E) analyzed 
for miR146b expression by qPCR (n=2, * indicates P<0.05 compared to the stem cells).  Data is 
presented as the mean ± S.E.M.   
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Hormonal stimulation results in the upregulation of miR146b in the mammary epithelial 
cells in vivo 
To further investigate the influence of steroid hormones on miR146b expression levels, we 
exposed virgin PMEC to estrogen (E) and progesterone (P) in vivo.  E + P hormonal pellets were 
inserted subcutaneously in virgin balb/c mice for three weeks.  Following treatment, the 
mammary glands were removed followed by PMEC isolation.  RT-qPCR revealed that E + P 
treatment resulted in a 4.6-fold (4.6± 0.09 SEM) increase (p<0.05) in miR146b expression levels 
compared to the non-treated controls (Fig. 2).  These data demonstrate that the expression of 
miR146b is regulated by sex hormones.  It is still unclear whether regulation of miR146b is a 
direct or indirect response to hormonal stimulation. 
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Figure 2.  In vivo administration of estrogen and progesterone results in upregulation of 
miR-146b expression in the mammary epithelial cells. (A) Quantitative RT-PCR of miR-146b 
in PMEC from virgin mice treated with estrogen and progesterone for 3 weeks compared to non-
treated virgin mice.  Data is presented as the mean ± S.E.M. (n=4, * indicates P<0.05). (B) 
Representative H&E sections from the hormone treated and control mice.   
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MiR146b promotes survival of the alveolar progenitor cells  
To assess the functional role of miR146b in the mammary alveolar progenitor cells, Locked 
Nucleic Acid oligonucleotides complementary to miR146b (LNATM, Exiqon) was used to 
knockdown and miR146b precursor transfection was used to overexpress miR146b in the 
pregnant primary epithelial cells derived from balb/C mammary glands and the CD derived 
alveolar progenitor cells.  RT-qPCR was used to examine miR146a levels after knocking down 
miR146b in pregnant PMECs to check the specificity of the knockdown.  The data showed a 
non-significant change in miR146a confirming that the knockdown is selectiv  for miR146b 
(Fig. 3A).  The cells were then collected at 72 hours post transfection, and stained with the 
LIVE/DEAD® Fixable Dead Cell Staining Kit.  The fluorescent dye can permeate the 
compromised membranes of dead cells and react with free amines both in the interior and on the 
cell surface.  Live-dead assay was performed on the distinct CD derived progenitor cells.  
MiR146b knockdown induced cell death selectively in the CD derived alveolar progenitor cells 
(Fig. 3B & C); and not in the ductal and the multipotent progenitor clnes.  Knockdown 
experiments showed no change in cell survival in the total population of PMECs derived from 
pregnant mouse mammary glands (data not shown).  However, knockdown of miR146b reduced 
the percentage of the alveolar luminal progenitors (lin-CD29lowCD24highCD61+) derived from 
pregnant mouse mammary glands by 45% ( 55%±9.7 SEM vs. 100%±1.8 SEM) compared to the 
controls (Fig. 3D & E ) after maintaining the cells in culture for 3 days.  Overexpression studies 
showed no significant increase in cell survival (data not shown).   
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Figure 3.  Knockdown of miR-146b leads to a reduction in the luminal progenitor 
subpopulation during pregnancy. (A) Quantitative RT-PCR of miR146a and miR146b in 
PMECs at 72 hours post-transfection with a miR146b LNA inhibitor (miR146b KD) and with 
non-silencing controls (NS; n=3, P<0.05). (B) Representative histogram of flow cytometry 
analysis for cells stained with the LIVE/DEAD® Fixable Dead Cell Staining Kit. Live-dead 
analysis was done in the alveolar progenitor cell line at 72 hours post-tran fection, and (C) 
quantification of the percentage of live cells (n=3, P<0.05). (D) Representative flow cytometry 
dot plots of PMECs at 72 hours post-transfection analyzed for the Lin-CD24+CD29loCD61+ 
population.  (E) The reduction in the CD24+CD61+ progenitor population from the Lin-CD29lo 
population of PMECs following knock down of miR-146b (n=3, * indicates P<0.05).  Data is 
presented as the mean  ±S.E.M.  
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MiR146b may promote alveolar progenitor cell maintenance by prefer ntial regulation of 
STAT3β 
We hypothesized that miR146b may promote alveolar progenitor cell survival during pregnancy 
and lactation by suppression of transcription factors with key roles during mammary 
development and or mammary involution process.  Previous studies have shown miR146b 
targets to include IRAK1, TRAF6, NFkB, and SMAD4 [45,46]. Since some miRNAs might also 
up-regulate mRNA expression [47,48], STAT5a and Elf5 two transcription factors that promote 
alveologenesis, were also examined [49,50].  For these experiments, miR146b knock-down in 
the CD derived alveolar progenitor clone has been done to screen for the ta gets.  As shown in 
Fig. 4A, knockdown of miR146b by LNA inhibitors did not up-regulate the expr ssion of known 
targets of miR146b.  These data suggest that the previously identified targ ts of miR146b are not 
regulated in the same manner in the mammary glands.  
STAT3 is a transcription factor that has been previously implicated in promoting mammary 
epithelial cell apoptosis at the onset of gland involution [51].  This finding prompted us to 
examine whether miR146b might target STAT3.  The 3’ UTR of the STAT3 gene was analyzed 
with the RNA22 target prediction program [52], and two putative miR146b binding sites were 
indentified in the STAT3α 3’UTR (1.9 kb) (Fig. 5A).  Knockdown of miR146b didn’t change 
STAT3α levels in the CD derived alveolar progenitor clone, and increased up to 2-fold in 
pregnant PMECs (2.1 ± 1.04 SEM vs. 0.9 ± 0.04 SEM), while knockdown of miR146b increased 
STAT3β protein expression (Fig. 4B), up to 2-fold in the CD derived alveolar progenitor clone 
(3.0 ± 0.4 SEM vs. 1.3 ± 0.09 SEM; p<0.05), and up to 6-fold in pregnant PMECs compared to 
the controls (5.9 ± 1.7 SEM vs. 1.1 ± 0.07 SEM; p<0.05) . To correlate miR146b expression with 
STAT3α/β  levels during mammary gland development, western blot of whole mammary glands 
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(undigested) from balb/c mice at different physiological stages of virgin, pregnant, lactating, and 
one, three, and six days post weaning were analyzed.  Interestingly, STAT3β levels were 
inversely correlated to miR146b levels at each physiological stage, while STAT3α   was equally 
expressed throughout all the stages (Fig. 4C).  As shown previously [51] and in this study (Fig. 
4D & E), there is an increase in STAT3α and STAT3β tyrosine phosphorylation (phosphor-
Y705-STAT3, present in both STAT3α and STAT3β) prior to a significant rise in 
STAT3α serine phosphorylation (phosphor-S727-STAT3,present only in STAT3α) beginning at 
day 2 post-weaning.  This suggests that STAT3β, either as homodimers or heterodimer with 
STAT3α or other transcription factors may contribute to the onset of mammary involution.  The 
contribution of specific STAT3 isoforms to the process of mammary epithelial apoptosis at the 
onset of involution is not known at this time.  The specific STAT3 isoform knockout mice have 
been generated but changes during mammary involution have not been evaluated [53].   
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Figure 4.  Effect of knockdown on miR146b known targets as well as on STAT3α/β. (A) 
Western analysis of Smad4, IRAK1, STAT5a, NFκB, TRAF6, ELF5, and β-Actin in the alveolar 
progenitor cell line 48 hours post-transfection in non-transfected (NT), S, and miR146b KD 
cells.  (B) Representative WB analysis of STAT3α/β levels in the alveolar progenitor clone 
(n=3) and in PMECs (n=4) at 48 hours post-transfection in NT, NS, and miR146b KD cells. (C-
E) Western blot analysis of total STAT3α/β (C); Phosphorylated tyrosine 705 (Phospho-Tyr-
STAT3) (D); Phosphorylated serine 727 (phosphor-ser-STAT3) (E) in total glands from mice at 
different physiological stages of virgin (V), pregnant (P), lactating (L), and involution days 1, 3, 
and 6 (C, E) and 10 (D) days post weaning (D-PW).   
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MiR146b binds to the 3’UTR of STAT3α 
In order to determine if the putative miR146b binding sites within the 3’ UTR of STAT3 gene, 
bind to miR146b, luciferase constructs where the 3’UTR of STAT3α was inserted downstream 
of the firefly luciferase reporter gene driven by SV40 promoter been utilized.  A chimeric mRNA 
is transcribed consisting of the firefly luciferase and the STAT3α 3' UTR sequence.  The vector 
also contains a renilla luciferase as an internal control downstream of the CMV promotor (Fig. 
5B).  In order to examine whether miR146b directly regulates STAT3α, 293T cells were 
transfected with the STAT3α 3’UTR reporter construct along with the miR146b precursor and 
the Pre-miR™ negative control.  Firefly luciferase activity was then measured and normalized to 
renilla luciferase activities in the same wells.  The results showed a statistically significant 
reduction (P<0.0001) in luciferase reporter activity when cells overexpressed miR146b 
compared with cells that expressed the Pre-miR™ negative control (Fig. 5C).  Luciferase 
reporter activity of the STAT3α3’UTR was also significantly lower in PMECs from pregnant 
mice, when miR146b expression is significantly higher, compared to luciferase activity in PMEC 
from virgin mice (P<0.0001; Fig. 5D). These data suggest that miR146b directly binds the 
3’UTR of STAT3α, and it is unclear how miR146b binds STAT3α ’UTR without significantly 
affecting STAT3α protein levels.  STAT3β may have a longer half-life resulting in a more stable 
protein compared to STAT3α.   A more stable/longer acting miRNA146b knock down strategy 
will need to be used in order to examine this possibility. Furthermore, it is still possible that 
miR146b binding is playing a role in STAT3 alternative splicing events, and these possibilities 
are being explored. Real-time RT–PCR results (data not shown) confirmed that STAT3α and 
STAT3β mRNA levels in miR146b knockdown cells at 48 hours after transfection remain 
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constant despite striking changes in protein expression. This finding rules out the affect of 
miR146b on splicing. However, site directed mutagenesis will be done to further validate these 
miR146b seed sites in the 3’UTR. The computationally predicted target sites in the miRNA-
binding seed regions will be mutated in order to examine the role of direct binding of miR146b 
to the 3’UTR of STAT3. 
There are conflicting reports about the STAT3β 3’UTR sequence. Ensemble [54] reports 
STAT3β 3’UTR length as 3.6 kb which is 1.7 kb longer than STAT3α, and has three putative 
miR146b binding sites.  Several attempts to clone this sequence have failed. On the other hand, 
NCBI [55] reports that the STAT3β 3’UTR to be 2 kb, which is identical to the STAT3α ’UTR 
with extra 90 base pairs in the 5’ end. This includes the same two putative binding sites as 
STAT3α. In this case, preferential STAT3β suppression may be because of the slightly longer 
3’UTR in STAT3β which may change the 3’UTR secondary structure in a way to make it more 
accessible for miR146b binding. Regulation of splicing events may also be another possible 
mechanism by which miR146b affects differential expression of STAT3β. We are in the process 
of cloning STAT3β 3’UTR luciferase reporter construct and examining its suppression by 
miR146b.   
Our results suggest that miR146b upregulation during lactation and pregnancy function to 
suppress STAT3β expression thus maintaining the survival of mammary alveolar progenit r 
cells.  Down regulation of miR146b during involution may result in removal of STAT3β 
suppression followed by alveolar progenitor cell death and involution.   
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Figure 5. MiR-146b targets the 3’UTR of STAT3α/β. (A) An illustration of the 3’UTR of 
STAT3α/β computationally predicted binding sites for miR-146b.  (B) Vector backbone of 
STAT3α/β 3' UTR reporter construct, STAT3α/β 3’UTR sequence was inserted downstream of 
the firefly luciferase reporter gene, driven by SV40 promoter for expression, renilla luciferase 
was used as an internal control. (C) Luciferase reporter activity of the STAT3α/β 3′UTR in 293T 
cells expressing miR146b, the non-silencing hairpin negative control and the luciferase positive 
control. Reporter activity decreases by 30% when cells are overexpr ssing miR146b. Each 
sample was normalized to Renilla luciferase activity. (n=6,*P<0.0001). (D) Luciferase reporter 
activity of the STAT3α/β  3’UTR in PMECs from pregnant and virgin mice without treatment, 
and in PMEC treated with the luciferase positive control. (n=6,*P<0.0001) 
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Discussion  
In this study we demonstrate that miR146b expression is highly upreg lated in the alveolar 
progenitor cells, during pregnancy and lactation and with hormonal (E plus P) stimulation. The 
transient knockdown of this miRNA affects the survival of luminal alveolar progenitor cells. 
This suggests that miR146b might be upregulated during the process of alveologenesis under the 
influence of hormones, causing suppression of key transcription factors inv lved in the process 
of involution and alveolar cell death  
Using flow analysis and cell sorting of mouse mammary epithelial cells, we showed miR146b to 
be highly expressed in the luminal progenitor subpopulation of cells.  Bockmeyer et al. studied 
the miRNA profiles of healthy human basal and luminal epithelial cells as well as basal and 
luminal breast cancers. The luminal and basal epithelial cells w re isolated by laser assisted 
microdissection from immunohistochemically stained tissue sections of healthy human breast 
specimens. Interestingly, miR146b was shown to be a basal-specific miRNA and to be expressed 
at higher levels in basal-like breast cancers compared to luminal A and B subtypes [39].  Other 
than this report, expression of miR146b and its role in mammary epithelial c ll development has 
not been previously described. 
Knock-down of miR146b in the luminal progenitor cells reduced cell survival.  We reasoned that 
miR146b might play a role in alveolar cell maintenance by regulating a known target such as 
IRAK1/TRAF6, NF-κB, or SMAD4 and or by regulating transcription factors with known roles 
during alveologenesis such as STAT5α and ELF5.  A review of the literature showed miR146b 
to regulate TGF-β signaling by repressing SMAD4 in thyroid cancers [46].  TGF-β has been 
shown to play an important role during mammary involution by inducing cellular apoptosis and 
alveolar collapse in the early stages of involution [56].  Furthermore, miR146b has been shown 
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to inhibit breast cancer cell invasion and migration by targeting IRAK1/TRAF6 and by down 
regulation of NF-kB signaling [45].  NF-kB has also been shown to destabilize STAT5α, a key 
transcription factor that promotes alveologenesis [57].  Interestingly, miR146b knockdown did 
not result in the up-regulation of any of these suspected targets.  Therefore, the previously 
identified miR146b targets may not be similarly regulated in the mammary glands.   
Since STAT3 transcription factors were reported to play key roles in mammary epithelial cell 
apoptosis at the onset of involution, we explored the role of miR146b in regulatin  STAT3 
isoforms. STAT3 has two main isoforms: the full-length STAT3α and the truncated STAT3β, by 
alternative mRNA splicing of exon 23 [15,16].  In STAT3β, the 55-amino acid C-terminal acidic 
transactivation domain of STAT3α is replaced by seven unique amino acid residues [16].  An 
important factor in STAT3 functional heterogeneity may be the existence of these two 
alternatively spliced isoforms. As suspected, miR146b knockdown resulted in up-regulation of 
STAT3 expression in both PMEC derived from pregnant mammary glands and in the alveolar 
progenitor cells.  However, the up-regulation of STAT3β isoform was higher than that of 
STAT3α.  Τhere are several possibilities for preferential regulation of STAT3b protein 
expression by MiR146b.  One is the existence of an additional miR146b binding site on the 
predicted STAT3b 3’UTR resulting in higher suppression of STAT3b protein translation [54].  
Another key mechanism, may be the regulation of alternative splicing events. The interplay 
between the miRNA and splicing regulation has been previously demonstrated.  These studies 
showed that miR124 and miR133 regulate the RNA-binding protein, polypyrimidine tract-
binding protein 1 (PTBP1).  PTBP1 is a global repressor of alternative pre-mRNA splicing in 
non neuronal cells [60,61].  Additionally, ESEfinder and PESX algorithms predicted a putative 
exonic splicing enhancer (ESE), which overlaps with one of the predicted miR146b binding 
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sites.  MiR146b binding to this overlapped region may regulate ESE. MiR146b could also 
indirectly regulate STAT3 alternative splicing by targeting key splicing factors. Real-time RT–
PCR results showed that STAT3α and STAT3β mRNA levels remain constant in miR146b 
knockdown cells despite striking changes in protein expression suggesting that miR146b most 
likely affects STAT3 protein translation. 
STAT3 is characterized by its capacity to activate different sets of genes in different cell types 
[62], and the different STAT3 isoforms seem to regulate cell survival and maintenance in a cell 
type and context specific manner by suppression and or activation of a variety of target genes 
[19].  STAT3β has been considered a dominant-negative factor by inhibiting STAT3α gene 
transactivation [17,18].  More recent studies have demonstrated that STAT3β may activate a 
specific set of genes and possess non-redundant functions to STAT3α. Zammarchi et. al used 
morpholino oligomers to redirect endogenous STAT3 alternative splicing from STAT3α to 
STAT3β.  This study showed that the induction of the STAT3β isoform in MDA-MB-435 cells 
caused cell death and tumor regression in the xenograft models.  The same study showed that 
STAT3 canonical target genes were not affected by the switch from STAT3α to STAT3β.  
Rather, a unique expression signature seems to be associated with the p ysiological α-to-β 
splicing shift [16].  In mammary gland development, it has become clear that STAT3 regulates a 
complex series of processes involving alveolar epithelial cell death during involution by 
maintaining the balance of inflammatory and anti-inflammatory signal ng [19].  The contribution 
of specific STAT3 isoforms to mammary involution process is still not known.  Mice knockout 
of specific STAT3 isoforms have been generated [53].  It is reportd that STAT3β  knockout 
mice are viable and fertile and capable of nursing their pups [53].  However, a detailed 
characterization of the mammary glands during involution has not been reported in these mice.  
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Our study clearly demonstrates that both isoforms of STAT3 are up-r gulated during involution.  
It would be interesting to decipher the contribution of specific STAT3 isoforms to the mammary 
involution process.    
Our study is the first to demonstrate that sex hormones regulate the expression levels of 
miR146b.  Furthermore, miR146b levels rise during mammary lactation and pregnancy.  
MiR146b up-regulation during pregnancy and lactation may mediate the maintenance of alveolar 
progenitor cells by selective suppression of STAT3β  and to a lesser extent STAT3α.  Following 
weaning and during the process of involution miR146b levels drop to basal levels which may 
result in the up-regulation of STAT3 isoforms and induction of alveolar cell death (Fig. 6; 
Model).  The LNA inhibitors induce a transient knockdown in miR146b [63], thus t ey are not 
suitable for long term in vivo transplantation studies.  It will be interesting to explore the effect of 
miR146b on alveologenesis by using a more stable knockdown and overexpression approach 
following in vivo transplantation.  The increasing reports demonstrating the role of miR146a/b in 
various types of human cancers, and our finding that miR146b may regulate the expression of 
STAT3 isoforms, known transcription factors that mediates both the process of involution and 
breast cancer, may shed light to the current understanding of cellular pathways leading to 
malignant transformation in the mammary epithelium. 
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Chapter III: Materials and Methods 
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Cell lines  
CommaDβ derived clones (SP-1, SP-3, SP-4, NSP-1, NSP-2, NSP-3, NSP-4, and NSP-5) were 
used. The alveolar progenitor (SP-3), ductal progenitor (NSP-2) and multipotent progenitor 
clones (NSP-5) have been previously described and characterized [2]. 293T cells (Clontech, Cat# 
632180) were used for luciferase reporter assays. 
 
Animals 
We used female balb/c mice which were either bred or purchased from Harlan Laboratories, Inc., 
IN, USA. We used mice in late pregnancy, as well as mice 24 hours, 3 days, and 6 days post 
weaning (involuting mammary glands), and virgin mice in the metestrous phase of the estrous 
cycle as confirmed by vaginal cytology [64]. Animal experiments were conducted following 
protocols approved by the University of Kansas Medical Center Institutional Animal Care and 
Use Committee.  
 
Mouse surgeries 
Slow-releasing pellets containing 50 µg of estradiol and 20 mg of progesterone for hormonal 
treatment were placed subcutaneously on the lateral side of the neck between the ear and 
shoulder. After 3 weeks, mice were sacrificed, and the mammary gl nds were excised. One 
mammary gland was processed for embedding, and the other mammary gland was used to 
recover the epithelial cells according to established protocol in our laboratory [65]. 
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Cell culture: 2D/ 3D ( MatrigelTM ) 
Primary mouse cells were grown and maintained in F12 (Invitrogen, Cat# 11765) supplemented 
with 5% fetal Bovine serum (Invitrogen, Cat# 10438026), 1% antibiotic/antimycotic reagents 
(AA; Invitrogen, Cat# 15240), 50µg/ml gentamicin (Sigma-Aldrich Cat# G1272), 1mg/ml 
hydrocortisone (Stem Cell Technologies, Cat# 07904), and 5 ng/ml epidermal growth factor.  
The CD derived clones (i.e. SP-3, NSP-2 and NSP-5) were grown in DMEM/F12 (Invitrogen, 
Cat# 11320) containing 2% fetal bovine serum, 5 ng/ml epidermal growth factor, 10 mM HEPES 
(Invitrogen, Cat#15630), 5µg/ml insulin, 50µg/ml gentamicin, and 1% antibiotic/antimycotic. 
293T cells were grown in DMEM (Sigma-Aldrich, Cat# D5796) containing 10% fetal bovine 
serum, and 1% antibiotic/antimycotic. The cells were grown in humidified incubator at 37oC and 
5% CO2.  For 3D culture, cells were plated in media containing 2% BD Basement Membrane 
Matrix MatrigelTM (BD Biosciences, Cat# 356234) on a thin film of, MatrigelTM.  Cell recovery 
was achieved using BD Cell Recovery Solution (BD Biosciences, Cat# 354253). 
 
Hematoxylin and eosin staining 
Excised mammary glands were fixed in 4% paraformaldehyde for 2 hours on ice followed by 
70% ethanol at 4oC until processing.  Tissues were embedded in paraffin and stained for 
hematoxylin and eosin according to established protocols [65].   
 
RNA Isolation and Quantitative PCR (qPCR): 
Total RNA was isolated with miRNeasy Mini Kit (Qiagen Cat# 217004) using the 
manufacturer’s protocol, and cDNA was synthesized from 250 ng of total RNA with miScript 
Reverse Transcription Kit (Qiagen Cat# 218061).  MiRNA and mRNA were measured using 
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miScript SYBR Green PCR Kit (Qiagen, Cat# 218073), and primers specific for hsa-miR-146b-
5p (IDT, Ref# 52053397). Reactions were performed in the StepOnePlus™ Real-Tim  PCR 
System and software (Applied Biosystems) in 96-well plates at 95oC for 15min, followed by 40 
cycles of 94oC for 15 s, 55oC for 30 s and 70oC for 30 s. Target gene expression was normalized 
to snU6: snU6 forward (IDT Ref.# 50315659), snU6 reverse (IDT Ref# 50315660).  The 
standard curve method was used for quantification.  
 
Microarray studies 
RNA from CDβ clones with growth potential (SP-3, NSP-1, NSP-2, NSP-5) and those without 
growth potential (NSP-3, NSP-4, SP-1, SP-4) were combined.  RNA quantity d quality 
(RIN>8) was checked using the Agilent Bioanalyzer.  Reverse transc iption was done using SA 
Biosciences RT2 miRNA First Strand Kit, RT2 miRNA PCR Array System (human cancer array, 
SABiosciences MAH-102E).  PCR array was loaded according to SA Biosciences protocol for 
loading map. The data was analyzed using the ∆∆CT method. 
(www.sabiosciences.com/pcrarraydataanalysis.php). 
 
FACS analysis and sorting 
Primary antibodies used were anti-mouse CD29 (APC/Cy7)-conjugated antibody (Biolegend, 
Cat# 102226), anti-mouse CD24 (PE)-conjugated antibody (BD Biosciences, Cat# 553262), anti-
mouse CD61 (Alexa Fluor 647)-conjugated (Biolegend, Cat# 104314), biotin-conjugated anti-
mouse CD31 (Biolegend, Cat# 102404), biotin-conjugated anti-mouse CD140a (Biolegend, Cat# 
135910), biotin-conjugated Rat anti-mouse CD45 (BD Pharmingen, Cat# 553077), biotin-
conjugated Rat anti-mouse Ter-119 (BD Pharmingen, Cat# 559971). The biotin-conjugated 
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antibodies were labeled using Streptavidin-V450 (BD Biosciences, Cat# 560797). Isotype 
control staining was performed using PE-conjugated anti-rat immunoglobulin G2bk (IgG2bk) 
antibody (Biolegend, Cat# 400635), APC/Cy7-conjugated mouse IgG2bk antibody (BD 
Pharmingen, Cat# 558061) and biotin-conjugated rat IgG2ak (IgG2ak) antibody (BD 
Pharmingen, Cat# 553928).  The cells were stained at a final concentration of 1:200 for 30 
minutes on ice followed by washes in Hanks’ balanced salt solution (Invitrogen, Carlsbad, CA, 
USA) containing 2% fetal bovine serum.  For live dead assay LIVE/DEAD® Fixable Dead Cell 
Stain Kit (Invitrogen, Cat# L34955) was used per manufacturer’s protocol.  FACS and data 
analysis were performed using the BD LSR II flow cytometer and FlowJo software (Tree Star, 
Inc., Ashland, OR, USA).  Cell sorting was performed using the FACS ria (BD Biosciences, 
San Jose, California, USA).  
 
MiR146b knock down and over expression in CDβ clones and in PMEC 
To overexpress miR-146b, 40nM of hsa-miR-146b-5p synthetic pre-miR precursors (Ambion, 
Ref# AM17100) were transfected into PMEC, along with the Pre-miRTMmiRNA Precursor 
Negative Control #1 (Ambion Ref# AM17110).  To knockdown miR-146b, 40 nM of miRCURY 
LNA microRNA inhibitor (Exiqon, Cat# 410066-04) for hsa-miR-146b-5pwas transfected into 
the cell lines and PMEC.   
Because the human and murine miR-146b-5p have identical sequences, the use of products, pre-
miRs and LNA inhibitors, designed for human are a perfect match for the mouse.  MiRCURY 
LNA microRNA inhibitor control (Exiqon, Cat#199004-04) was used as a negativ  control.  In 
both cases, cells were seeded in a six-well plate and transfected 24h later with LipofectamineTM 
2000 Transfection Reagent (Invitrogen, Cat# 11668-019) in the media described abov , without 
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serum or antibiotic present. 24h after transfection the cells werenourished with 1% serum. 
Seventy-two hours post-transfection, the cells were washed with PBS and recovered for analysis 
as described above. 
 
Ugagaacugaauuccauggguu 146a 
Ugagaacugaauuccauaggcu 146b 
 
Western blot  
Cells were lysed on ice using RIPA buffer (50 mM Tris-HCL, pH 7.4, 150 mM NaCl, 2 mM 
EGTA, 0.25% deoxycholate and 1% Triton X-100) containing protease inhibitors (Calbiochem, 
Cat# 535140) and phosphatase inhibitors (Calbiochem, Cat# 524627).  The protein extracts were 
prepared by collecting supernatants after centrifugation at 12,000 xg  at 4oC for 30 min. The 
protein concentrations were measured using BCA protein assay kit according to manufacturer’s 
protocol (Thermo Scientific, Cat# 23250).  Ten µg of protein was separated on an 8-10% SDS-
PAGE gel, transferred onto PVDF membrane (Millipore, 0.45 mm) in Tris-Glycine (25 mM tris 
and 192 mM glycine, pH 8.3, BioRad, Cat# 161-0771) containing 20% v/v methanol at 100V for 
2 hours.  The PVDF membrane was blocked with 5% non-fat dry milk in TBS containing 0.05% 
Tween 20 (TBST) at room temperature for 1 hour.  The blots were washed three times for 10 
min with TBST before incubating with primary antibody in TBST for 1 hour at room 
temperature or overnight at 4oC.  The primary antibodies STAT5a (Invitrogen, Cat# 13-3600), 
STAT3 (K-15; Santa Cruz, Cat# sc-483), p(Ser)-STAT3 (23G5; Santa Cruz, at# sc-56747), 
p(Tyr)-STAT3 (Cell signaling, Cat# 9131S) TRAF6 (H-274; Santa Cruz, Cat# sc-7221), IRAK1 
(H-273; Santa Cruz, Cat# sc-7883), STAT5a (ST5a-2H2; Invitrogen, Cat# 13-3600), NFkB p65 
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(C22B4;Cell Signaling, Cat#  4764), ELF5 (N-20; Santa Cruz, Cat# sc-9645), and Smad4 (B-8; 
Santa Cruz, Cat# sc-7966) were used at a dilution of 1:1000.  Following primary antibody 
incubation, the membranes were washed thoroughly with TBST (3x, 10 min each) and incubated 
with horseradish peroxidase (HRP) conjugated secondary antibodies Donkey a ti-rabbit-HRP 
(Jackson, Cat# 711-035-152) at 1:10,000 or goat anti-mouse-HRP (Santa Cruz, Cat# sc2005) at 
1:10,000 in TBST containing 1% milk for 1 hour at room temperature.  After washing with 
TBST (3x, 10 min each), the bands were visualized with enhanced chemiluminescence (ECL) , 
SuperSignal West Femto Kit (Thermo Scientific, Cat# 34095) and the blots were digitalized 
using Auto Chemi systems (UVP Inc., Upland, CA). The membranes were stripped by 
incubating with stripping buffer (50 mM Tris-HCL, pH 6.8, 2% SDS, and 100 mM β-
marcaptoethanol) at 50oC for 30 min followed by washing with TBST  and re-probed with β-
actin antibody (Santa Cruz, Cat# sc1616, 1:1500 dilution) followed by anti-goat I G HRP (Santa 
Cruz, Cat# sc2350, 1:10000 dilution) for loading control.  Densitometry analysis wa  performed 
using LabWorks software (UVP Inc., Upland, CA). 
 
Luciferase Reporter Constructs 
293T cells (Clontech, Cat# 632180) were plated in 6-well plates.  After 24h, the cells were 
transfected with 1.0 µg of STAT3α 3' UTR miRNA target sequence expression clone in pEZX-
MT01 vector with fLuc (Genecopoiea, Cat# MmiT043695 ) and 40nM of miR-146b precursor 
miRNA (Ambion, Ref# AM17100) and miRNA control (Ambion Ref# AM17110). The cells 
were transferred to a 96-well plate 18 hours after transfection and cultured for another 24 hours.  
Both firefly luciferase and renilla luciferase activities were measured using GeneCopoeia Luc-
Pair™ miR Luciferase Assay kit (Genecopoiea, Cat# LPFR-M030) according to the 
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manufacturer’s protocol and data was recorded on BioTek Microplate Reader using 
Gen5TMsoftware. Firefly luciferase activity was normalized with renilla luciferase activities in 
the same well. 
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Chapter IV: Conclusion 
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In conclusion, our study is the first to demonstrate that miR146b is a hormonally regulated 
miRNA, which is up-regulated during pregnancy and lactation, and its expression is higher in the 
luminal progenitor subpopulation of cells. MiR146b might not only be involved in normal cell 
function, but its mis-regulation might contribute to cancer initiation, progression and metastasis. 
We showed that miR146b knockdown reduces the luminal progenitor cells, which might be 
important in the etiology of cancer. Furthermore, we demonstrated that miR146b can regulate the 
expression of different STAT3 isoforms, especially STAT3β. The role of STAT3 in mammary 
gland involution has been widely accepted, but the individual role of STAT3 isoforms is still 
unclear. Generation of loss-of-function mouse models for miR146b will be required to establish 
whether miR146b is essential for normal development, and the functional role of STAT3β in 
mammary gland involution requires further investigation. Finally, our results led us to a 
proposed mechanism by which miR146b my play a role in alveologenesis and mammary gland 
remodeling. In this model, miR146b up-regulation during pregnancy and lactation may mediate 
the maintenance of alveolar progenitor cells by selective suppression of STAT3β and to a lesser 
extent STAT3α.  Following weaning and during the process of involution miR146b levels drop 
to basal levels which may result in the up-regulation of STAT3 isoforms and induction of 
alveolar cell death (Fig. 6; Model).   
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Figure 6. A proposed model for miR-146b regulation of alveolar progenitor cell 
maintenance. Mammary epithelial cell hierarchy begins with asymmetric self-renewal in the 
stem cells, which generate multipotent and bipotent ductal and alveolar pr genitor cells.  Ductal 
and alveolar progenitor cells give rise to luminal and myoepithelium-restricted progenitors. 
During pregnancy and lactation, miR146b may be upregulated under the influence of estrogen 
and progesterone in the alveolar progenitor cells to suppress STAT3α/β and to promote the 
survival of these cells. During involution, miR-146b may be down regulated in the alveolar 
progenitors to de-represses STAT3α/β followed by cell death in the luminal alveolar cells and 
the onset of involution. 
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